Vedanthan, Rajesh; Bernabe-Ortiz, Antonio; Herasme, Omarys I; Joshi, Rohina; Lopez-Jaramillo, Patricio; Thrift, Amanda G; Webster, Jacqui; Webster, Ruth; Yeates, Karen; Gyamfi, Joyce; +22 more... Ieremia, Merina; Johnson, Claire; Kamano, Jemina H; Lazo-Porras, Maria; Limbani, Felix; Liu, Peter; McCready, Tara; Miranda, J Jaime; Mohan, Sailesh; Ogedegbe, Olugbenga; Oldenburg, Brian; Ovbiagele, Bruce; Owolabi, Mayowa; Peiris, David; Ponce-Lucero, Vilarma; Praveen, Devarsetty; Pillay, Arti; Schwalm, Jon-David; Tobe, Sheldon W; Trieu, Kathy; Yusoff, Khalid; Fuster, Valentin; (2017) Innovative Approaches to Hypertension Control in Low- and Middle-Income Countries. CARDIOLOGY CLINICS, 35 (1). pp. 99-115. ISSN 0733-8651 DOI: https://doi.org/10.1016/j.ccl.2016.08.010

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4654711/

DOI: https://doi.org/10.1016/j.ccl.2016.08.010

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Innovative Approaches to Hypertension Control in Low- and Middle-Income Countries

Rajesh Vedanthan, MD, MPH,1 Antonio Bernabe-Ortiz, MD, MPH,2 Omarys I. Herasme, MPH,1 Rohina Joshi, MBBS, PhD, MPH,3 Patricio Lopez-Jaramillo, MD, PhD,4 Amanda G. Thrift, PhD,5 Jacqui Webster, PhD,3 Ruth Webster, PhD, MIPH,5,6 Karen Yeates, MD, MPH,6

Corresponding Author: Rajesh Vedanthan, MD, MPH, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, rajesh.vedanthan@mssm.edu.

Authors Contact Information:
Antonio Bernabe-Ortiz, CRONICAS, Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru, antonio.bernabe@upch.pe
Omarys I. Herasme, Icahn School of Medicine, Mount Sinai Hospital, New York, USA, omarys.herasme@mssm.edu
Rohina Joshi, The George Institute for Global Health, University of Sydney, Sydney, Australia, rjoshi@georgeinstitute.org.au
Patricio Lopez-Jaramillo, Research Institute FOSCAL, Bucaramanga, Colombia, jlopezj@gmail.com
Amanda G. Thrift, Monash University, School of Clinical Sciences at Monash, Health, Melbourne, Australia, amanda.thrift@monash.edu
Jacqui Webster, The George Institute for Global Health, University of Sydney, Sydney, Australia, jwebster@georgeinstitute.org.au
Ruth Webster, The George Institute for Global Health, University of Sydney, Sydney, Australia, rwebster@georgeinstitute.org.au
Karen Yeates, Queens University, School of Medicine, Ontario, Canada, yeatesk@queensu.ca
Joyce G Yamfi, New York University, School of Medicine, New York, USA, Joyce.Yamfi@nyumc.org
Merina Jeremia, Samoan Ministry of Health, Apia, Samoa, merinal@health.gov.ws
Claire Johnson, The George Institute for Global Health, University of Sydney, Sydney, Australia, cjohnson@georgeinstitute.org.au
Jemima H. Kamano, Moi University, School of Medicine, Eldoret, Kenya, shoinehoino@gmail.com
Maria Lazo-Porras, CRONICAS, Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru, maria.lazo@upch.pe
Felix Limbani, Centre for Health Policy, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa, felix.limbani@wits.ac.za
Peter Liu, University of Ottawa, Ontario, Canada, peter.liu@utoronto.ca
Tara McCready, Population Health Research Institute, Hamilton, Canada, tara.mccready@phri.ca
J. Jaime Miranda, CRONICAS, Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru, jaime.miranda@upch.pe
Sailesh Mohan, Public Health Foundation of India, New Delhi, India, smohan@phfi.org
Brian Oldenburg, University of Melbourne, School of Population and Global Health, Melbourne Australia, brian.oldenburg@unimelb.edu.au
Olugbenga Ogbedegbe, New York University School of Medicine, New York, USA, olu@gbedegbe@nyumc.org
Bruce Ovbiagele, Medical University of South Carolina, Charleston, USA, ovibes@musc.edu
Mayowa Owolabi, University of Ibadan, Ibadan, Nigeria, mayowaowolabi@yahoo.com
David Peiris, The George Institute for Global Health, University of Sydney, Sydney, Australia, dpeiris@georgeinstitute.org
Vilainoma Ponce-Lucero, CRONICAS, Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru, vilainona.ponce1@upch.pe
Arti Pillay, Fiji National University, Suva, Fiji, arti.pillay@fni.ac.fj
Jon-David Schwalm, Population Health Research Institute, Hamilton, Canada, schwalm@mcmaster.ca
Sheldon W. Tobe, University of Toronto, Ontario, Canada, sheldon.tobe@sunnybrook.ca
Kathy Trieu, The George Institute for Global Health, University of Sydney, Sydney, Australia, ktrieu@georgeinstitute.org.au
Khalid Yusoff, UCSI University, Kuala Lumpur, Malaysia, khalid@ucsiuniversity.edu.my
Valentin Fuster, Icahn School of Medicine, Mount Sinai Hospital, New York, USA, valentin.fuster@mssm.edu

Disclosure Statement:
The authors have nothing to disclose.

Authors' Contributions
All authors were involved in the initial draft of this manuscript, made continual input as the drafts progressed, and approved the final draft for submission. The content within is solely the responsibility of the authors and does not necessarily represent the official views of the Global Alliance for Chronic Diseases funding agencies or affiliates.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Joyce Gyamfi, MS7, Merina Ieremia, PGDHS8, Claire Johnson3, Jemima H. Kamano, MBChB, MMed9, Maria Lazo-Porras, MD2, Felix Limbani, MPH10, Peter Liu, MD11, Tara McCready, PhD, MBA12, J. Jaime Miranda, MD, PhD, MSc2, Sailesh Mohan, MD13, Olugbenga Ogedegbe, MD, MS, MPH7, Brian Oldenburg, PhD, MPsych14, Bruce Ovbiagele, MD, MSc15, Mayowa Owolabi, MBBS16, David Peiris, MBBS, PhD, MIPH3, Vilarmina Ponce-Lucero2, Devarsetty Praveen, MBBS, MD, PhD17, Arti Pillay, PGDPH18, Jon-David Schwalm, MD, MSc12, Sheldon W. Tobe, MD, MScCH19, Kathy Trieu, MPH3, Khalid Yusoff, MBBS20, and Valentin Fuster, MD, PhD1

1Icahn School of Medicine at Mount Sinai, New York, USA

2CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru

3The George Institute for Global Health, University of Sydney, Sydney, Australia

4Research Institute FOSCAL, Bucaramanga, Colombia

5Monash University School of Clinical Sciences at Monash Health, Melbourne, Australia

6Queens University School of Medicine, Ontario, Canada

7New York University School of Medicine, New York, USA

8Samoa Ministry of Health, Apia, Samoa

9Moi University College of Health Sciences, Eldoret, Kenya

10University of the Witwatersrand, Johannesburg, South Africa

11University of Ottawa, Ontario, Canada

12Population Health Research Institute, Hamilton, Canada

13Public Health Foundation of India, New Delhi, India

14University of Melbourne, School of Population and Global Health, Melbourne Australia

15Medical University of South Carolina, Charleston, USA

16University of Ibadan, Ibadan, Nigeria

17The George Institute for Global Health, Hyderabad, India

18Pacific Research Centre for the Prevention of Obesity and Non-Communicable Diseases at Fiji National University, Suva, Fiji

19University of Toronto, Ontario, Canada

20UCSI University, Kuala Lumpur, Malaysia

Abstract

Elevated blood pressure, a major risk factor for ischemic heart disease, heart failure, and stroke, is the leading global risk for mortality. Despite global efforts to combat hypertension, it continues to exert a significant health and economic burden on low- and middle-income country (LMIC) populations, thereby triggering the need to address the problem by way of novel approaches. The
Global Alliance for Chronic Diseases has funded 15 research projects related to hypertension control in low-resource settings worldwide. These research projects have developed and evaluated several important innovative approaches to hypertension control, including: community engagement, salt reduction, salt substitution, task redistribution, mHealth, and fixed-dose combination therapies. In this paper, we briefly review the rationale for each of these innovative approaches, as well as summarize the experience of some of the research teams in these respective areas. Where relevant, we also draw upon the wider literature to illustrate how these approaches to hypertension control are being implemented in LMICs. The studies outlined in this report demonstrate innovative and practical methods of implementing for improving hypertension control in diverse environments and contexts worldwide.

**Keywords**

Hypertension; Low- and middle-income countries; Community engagement; mHealth; Task redistribution; Salt reduction; Salt substitution; Polypill

**Introduction**

Cardiovascular disease (CVD) is the leading cause of mortality in the world, resulting in 17.3 million deaths annually, with 80% of these deaths occurring in low- and middle-income countries (LMICs).

Elevated blood pressure, a major risk factor for ischemic heart disease, heart failure, and stroke, is the leading global risk for mortality. Despite global efforts to combat hypertension, treatment and control rates are very low in LMICs. Given the continued significant health and economic burden on LMIC populations, there is an urgent need to address the problem by way of novel approaches.

Founded in 2009, the Global Alliance for Chronic Diseases (GACD), funds, coordinates, and facilitates global collaborations in implementation research, focusing on the prevention and treatment of chronic non-communicable diseases in LMICs and vulnerable populations in high-income countries. The first round of GACD-sponsored research projects focused on hypertension, and included 15 research teams from around the world. These research projects have involved the development and evaluation of several important innovative approaches to hypertension control, including: community engagement, salt reduction, salt substitution, task redistribution, mHealth, and fixed-dose combination therapies.

In this paper, we briefly review the rationale for each of these innovative approaches, as well as summarize the experience of some of the GACD teams in these respective areas. Where relevant, we also draw upon the wider literature to illustrate how these approaches to hypertension control are being implemented in LMICs.

**Community Engagement**

Health care delivery and health systems often fail to meet the needs and expectations of those who need them. Community engagement seeks to address this problem by optimizing the appropriateness and alignment of health care to the cultural, social, economic, and environmental setting. It encompasses participation, mobilization, and
empowerment (Figure 1). Participation refers to the active or passive engagement of the community in health services. Mobilization furthers this engagement through facilitation by health professionals, while empowerment involves a capacity-building process to engage communities in planning, implementing and/or evaluating activities to achieve more sustainable health improvements. Community engagement has shown promise in supporting interventions to improve health outcomes related to both HIV/AIDS as well as maternal and child health. However, traditional methods for determining efficacy of community engagement are inadequate because there are significant challenges in teasing out the independent effects of the intervention vis a vis the process of community engagement itself.

Four GACD projects described herein have been conducted in Tanzania, Kenya, Colombia, Malaysia, India, and Canada. The investigators of these GACD projects have adopted a diverse range of community engagement activities, targeted at both individuals and systems, in order to identify barriers and facilitators for the care of hypertension, and thereby tailor the intervention to the local context (Table 1). Prior to initiating each of these studies, investigators and research staff met with community leaders, health personnel, and other relevant community stakeholders, to facilitate entry to the communities and to appropriately contextualize their approaches. Components of community engagement included (1) individual interviews with diverse stakeholders; (2) focus group discussions (FGDs) with hypertension patients; (3) workshops with local community health workers (CHWs) and clinicians to refine the intervention and training materials, thus enhancing the capacity of CHWs to deliver the intervention by employing relevant and easy-to-use tools; (4) community social events and gatherings; and (5) mabaraza (singular baraza), traditional East African community gatherings, conducted among individuals with elevated blood pressure and CHWs to complement the purposive sampling inherent in FGDs. The baraza is a unique and novel qualitative research setting which has been used as a form of participatory action research, and allows organization of a diverse and heterogeneous large group of individuals. In Tanzania and Canada, the team used an adapted tool called I-RREACH: Intervention and Research Readiness Engagement and Assessment of Community Health Care. This tool was developed using a community-based consensus method, and is rooted in participatory principles, equalizing the importance of the knowledge and perspectives of researchers and community stakeholders while encouraging respectful dialogue. The I-RREACH tool is an engagement and assessment tool for improving the implementation readiness of researchers, organizations and communities in complex interventions, and consists of three phases: fact finding, stakeholder dialogue, and community member/patient dialogue. Another study being conducted in Canada, Malaysia, and Colombia leveraged non-medical community events for the purposes of screening, recruitment, intervention implementation, and follow-up. Using process evaluation, the GACD projects hope to add to our understanding of how community engagement can be used to support and strengthen programs aimed at improving hypertension control. Such an approach can be applied to more chronic diseases in low-resource settings worldwide.

The need for this research is illustrated by work elsewhere. Although it may seem self-evident that a more participatory approach will improve the acceptability, and thus effectiveness of interventions, this is not fully supported by the evidence. Two projects...
conducted in Cape Town, South Africa, and El Paso, Texas, used community-based participatory research approaches to design an intervention to manage hypertension and diabetes. Positive results included: 1) improved self-efficacy to manage hypertension, 2) greater improvements in health behaviours in the intervention group than in the control group, 3) the development of culturally appropriate health education materials specifically developed for low-literacy populations, and 4) inclusion of learnings into local health sector planning for prevention and control of hypertension and diabetes. Although the authors stated that the materials were well received by participants in one study, no evidence for clinical success of community engagement was provided in either study.

Salt Reduction

Evidence shows that a reduction in the consumption of sodium—found in table salt and naturally occurring foods such as milk, eggs, meat, and shellfish—decreases blood pressure in adults and diminishes the risk of CVD. While there is controversy about the most appropriate target for sodium intake, higher sodium intake in general is associated with poorer outcomes. The World Health Organization (WHO) recommends a reduction in sodium intake to < 2 g/day in adults. In 2013, member states of the United Nations established a target to reduce the average population salt intake by 30% by 2025, and 75 countries now have strategies in place to achieve this target. The majority of these national programs are multifaceted and include initiatives such as industry engagement to lower salt content in foods, consumer education and awareness, establishing front-of-pack labelling schemes and nutrition standards for foods procured in public settings.

Three of the GACD Hypertension programs have implemented innovative salt reduction programs to reduce blood pressure. The first step in any program is to measure existing consumption patterns. These projects measured salt intake using 24-hour urine excretion and tried to understand people’s knowledge and eating behaviors through community surveys. Average daily salt excretion at baseline varied from 7 gm (Samoa); 11 gm (Fiji); 9.5 gm and 8.6 gm (Andhra Pradesh and Delhi/Haryana, respectively, India); to 12.6 gm (Shanxi, China). The information on diet was then used to inform the different intervention strategies. Based on the WHO’s framework for Creating an Enabling Environment for Salt reduction, the project in Fiji and Samoa used multi-faceted intervention programs to reduce salt in the food supply, while concurrently implementing media and community mobilization campaigns to increase awareness. A parallel project in Andhra Pradesh and Delhi/Haryana, India, used community surveys and stakeholder mapping and established a comprehensive food composition database (based on the George Institute’s leading FoodSwitch innovation for monitoring the food supply and identifying healthy choices). This information is being used to inform the development of a government-led salt reduction strategy for India. The Little Emperor project in China trained children to encourage their parents to reduce salt intake. Implemented in the northern province of Shanxi, the researchers taught the children about the harmful effects of a salty diet and asked them to share the messages with adults back home. Innovative children’s approaches including hiding the salt pot, making up rhymes or using their status as “Little Emperors” to refuse to eat unhealthy foods, led to a 26% reduction in participants’ salt intake in less than 4 months. More than 270 million people currently have hypertension in China; therefore, if
applied nationally, such a strategy could have substantial health and potential economic benefits.

Post-intervention monitoring in Fiji and Samoa is being finalized and has been supplemented through an in-depth process evaluation to better understand how the interventions have been implemented and potential barriers to effectiveness. Some of the challenges have included the changing political environment, difficulties of multi-sectoral action and limited experience in engaging the food industry. Mainstreaming the agendas with the Health Ministries in the different countries has been key to overcoming some of these problems. The lessons are being documented and will be disseminated widely through the WHO Collaborating Centre for Population Salt Reduction at the George Institute for Global Health, thus supporting rapid and effective translation of research into policy and practice. These and other studies will help to elucidate and clarify the relationship between sodium reduction and CVD.

**Salt substitution**

In addition to salt reduction, salt substitution is an innovative, non-pharmacological approach to reduce blood pressure. It involves the partial replacement of sodium chloride with any combination of other salt containing potassium, magnesium, or aluminum. A meta-analysis from six randomized controlled trials using different combinations of salt substitute in comparison to usual salt found, in pooled results, that a salt substitute reduced systolic blood pressure by −4.9 mm Hg (95% CI: −7.3, −2.5) and diastolic blood pressure −1.5 mm Hg (95% CI: −2.7, −0.3). However, in the subgroup analysis, the effect was significant only among individuals with hypertension.30

One of the GACD projects, conducted in Peru,31 is using a population-wide approach to test the effect on blood pressure of replacing regular salt by an iodine-fortified substitute containing 25% potassium chloride and 75% sodium chloride. This involves a pragmatic stepped wedge trial design, in which the intervention is progressively implemented at random in six villages. The study has been implemented in two phases (Figure 3). The first phase was exploratory and included: (a) formative in-depth interviews and FGDs; (b) a triangle taste test, which found that a salt with 25% of potassium chloride was indistinguishable from regular salt;32 and (c) the development of the social marketing campaign targeting primarily women responsible for cooking at their home, and focused on promoting consumption and adherence of participants to the potassium-enriched salt. The second phase involved implementation of the intervention. The salt substitute has progressively replaced the common salt used in households, relying heavily on the social marketing/branding campaign as well as educational entertainment delivered by trained community health workers. Salt replacement has been implemented at households, bakeries, community kitchens and restaurants in each village.

Previous salt substitute strategies have focused on delivering the salt substitute product among participants with a diagnosis of hypertension, focusing almost exclusively on the hypertension status of the participant rather than on the product’s concept. For instance, the salt substitute used in other studies were no different between intervention and control arms.
The novelty of the Peru study relies on the implementation mechanisms that were developed and put in place, at the community level, aiming to increase the uptake of the salt substitute product as well as ensuring its sustained used over time in populations irrespective of hypertension status. To date, acceptability of the salt substitute to participants has been successful with very low rates of adverse effects related to its use. The study is ongoing and the fourth wedge has been concluded, with expected outcomes in early 2017. If successful, this project’s implementation approach may serve as a model for other LMIC settings.

**Task Redistribution**

In most countries, primary care physicians are the main providers of healthcare for individuals with CVD. Unfortunately, most LMICs have an inadequate number of physicians, especially in rural and remote regions where a majority of the population reside. According to the WHO Global Health Observatory, there are 0.3 physicians available for every 1000 population in low income countries, 1.2 physicians per 1000 population in lower-middle income countries, and 2.0 per 1000 population in upper-middle income countries. In response to this physician workforce shortage, appropriate strategies for task redistribution—from doctors to a team consisting of doctors and trained non-physician health workers (NPHWs)—have been developed and implemented, especially in the areas of maternal and child health needs, and HIV/AIDS.

Task redistribution describes a situation where a task normally performed by a physician is shared between physicians and other health workers with a different or lower level of education and training (Figure 4). Task redistribution may be aided by technology, clear guidelines, or close supervision by physicians, to help standardize the performance and interpretation of certain tasks, therefore allowing them to be performed by NPHWs. Systematic reviews on task-redistribution for CVD management indicate that not many studies have been conducted to test the effectiveness of task redistribution, and that further operational research, including detailed process evaluation, is required to understand the complexity, effectiveness, and cost-effectiveness of task-redistribution within different country contexts. Recent studies involving task-redistribution have shown that NPHWs can be effectively trained in the implementation of CVD prevention and management guidelines, successfully screen individuals at high-risk of CVD, provide lifestyle education and adherence to patients, and support patients with acute coronary syndrome. This approach has also been shown to be cost-effective for chronic disease care in the LMIC context. While there are now some published studies concerning the effectiveness of task-redistribution, there remain large evidence gaps and obstacles regarding the translation of positive research findings into routine health care delivery in LMICs, while also ensuring quality of care, safety, and patient acceptability. These shortcomings notwithstanding, task redistribution for the prevention and control of hypertension and other chronic diseases presents a great opportunity that could increase access to care, reduce health care costs, free up physician time for other tasks, and increase system efficiency in the long-term.
Eight of the GACD projects included a component of task redistribution for the detection and management of hypertension. These include the redistribution of tasks related to hypertension screening, referral to clinicians, providing lifestyle advice, and support for adherence to medications to NPHWs. All the studies supported NPHWs by training them for two to six days, followed by re-training where required. Some studies facilitated task redistribution by using mHealth technology, whereby NPHWs used electronic decision support tools to screen individuals in the community and link them to hypertension care. Process and interim evaluations have identified that the main barriers to task-redistribution include resistance from other health professionals; increasing NPHW workload due to additional tasks; complexity of training materials; health system-related issues such as non-availability or non-functioning BP machines, poor drug supply, lack of physician availability for referral; regulatory restrictions including the inability to prescribe medications; and low remuneration of NPHWs. The key enablers included an increase in the enthusiasm and motivation of NPHWs to be trained and take on new roles, as well as a reduction in the physician workload leading to improved performance. All of these studies are currently in progress and will have effectiveness and cost-effectiveness results in the near future.

mHealth

mHealth is the use of mobile phones to improve and support health, and can be used for a variety of purposes to connect clinicians, other health workers including CHWs, and patients or patient caregivers (Figure 6). mHealth can be used to provide health education, promote behavior change, facilitate decision support in diagnosis and management of a wide variety of conditions, support diagnostic testing, or link medical records. Evidence for benefits of mHealth is widespread among a variety of high-income country settings, and further data are emerging on the use of mHealth in LMICs with respect to the impact on clinical outcomes, processes of care, health care costs and health related quality of life. There is great potential for the use of mHealth for hypertension management in LMICs as mobile phone ownership is high and growing rapidly, even among the poor. However, there still remain research gaps with a relatively limited number of studies in this area, particularly in hypertension.

Five projects within the GACD research network have a mHealth component at their core, or in conjunction with other innovations, in order to address barriers within health systems and to optimize opportunities for the detection and management of hypertension. The projects are taking place in communities in rural Kenya, rural Tanzania, both urban and rural Colombia and Malaysia, rural and remote Aboriginal communities in Canada, Nigeria, and rural India. All of the projects are utilizing either a smartphone- or tablet-based tool designed for use by community health workers (CHWs) to improve hypertension care; facilitate improved identification, follow-up, and tracking of patients; promote adherence to medications; and improve education of patients and CHWs. All of the programs have a component of real-time decision support. In addition, the Nigerian and Tanzanian/Canada program also send educational, behaviour change communication messages via text message directly to patients’ mobile phones, while the India project uses interactive voice response messaging because text messaging was not acceptable in this setting. The Kenya and India
projects embed educational messaging in novel audio-visual formats, so that CHWs can share these audio-visual materials to patients during home visits.

Some unique features among the mHealth innovations and programs should be highlighted. The programs in Kenya and India use an open-source platform called Open Data Kit, which has been utilized successfully to provide clinical decision source tools for HIV care. The Indian program also provides access to a mobile device that allows primary care physicians in government health clinics to access the health information of participants screened by CHWs; the device offers decision support for those participants identified at high CVD risk. This feature is also a component of the Tanzania-Canada program, whereby health center nurses and clinical officers can access all BP measurements taken for a patient by CHWs. A substudy of the Tanzania project is also evaluating the effectiveness of a phone-based drug voucher program to ensure the authenticity of drug supply and adherence factors in hypertension control. The Nigerian program is targeting patients who have experienced a stroke, who are at high risk for another stroke. Across the programs there have been common challenges, which include both technical and human factors. Technical factors have included mobile network coverage and server issues. Human factors have included overcoming end-user challenges with the new technology, as well as implementation delays due to government approval processes, equipment procurement delays, misalignment of incentives, competing obligations, and excessive workload for the health providers who are utilizing these new systems.

**Polypill – Fixed-dose Combination Therapy**

Most patients with hypertension generally require blood pressure (BP) lowering medication from multiple classes to achieve adequate control. The need for titration of medication and addition of multiple classes of drug requires multiple physician visits and this in itself can lead to poor adherence to prescribed medication and poor attendance at scheduled visits. The requirement to take multiple medications in complex regimes also encourages poor adherence. For physicians, the need for repeated up-titrating or adding extra medications can lead to inertia and tacit acceptance of inadequate BP control. Initiating anti-hypertensive treatment with dual combination therapy not only accelerates the time taken to achieve control but also attains a lower final target. For the patient, improved adherence has also been demonstrated without worsening the side effect profile. Further benefits in BP control can also result from simplifying up-titration regimes.

Use of multi-modal fixed-dose combination pills (FDCs)—also known as ‘polypills’—containing not only multiple low-dose blood pressure-lowering drugs, but also statins and aspirin, has the potential to reduce a person’s cardiovascular risk beyond that achieved by simply lowering their blood pressure, by addressing multiple risk factors concurrently in a single pill. Multiple large clinical trials have shown that use of ‘polypills’ in patients at high risk of CVD improves adherence to long-term medication with consequent improvements in cholesterol and blood pressure measurements, and are highly acceptable to patients and physicians alike (Figure 5). The recently published HOPE-3 study utilized a polypill type strategy in patients at moderate CVD risk and showed a significant reduction in CV events in patients with hypertension. While reducing BP was a benefit only in those in the
hypertensive range, lowering cholesterol had beneficial effects in reducing fatal and non-fatal cardiovascular events overall.\(^75\) Evidence is needed, however, on the implementation of such a strategy in real-life clinical contexts rather within the constraints of a highly regulated clinical trial.

The GACD has funded two projects looking at whether use of FDCs will improve management of hypertension, and also overall CVD risk, in real-life clinical contexts in several LMICs. The TRIple Pill vs. Usual care Management for Patients with mild-to-moderate Hypertension (TRIUMPH) study,\(^76\) is a prospective, open, randomized controlled clinical trial (n=700) of a fixed dose combination blood pressure-lowering pill (“Triple Pill”) -based strategy compared to usual care among individuals with persistent mild-to-moderate hypertension on no or minimal drug therapy. The aim is to see whether early use of low dose FDC medications will result in faster and better control of blood pressure. The HOPE-4 study, being conducted in 50 urban and rural communities in Canada, Colombia, and Malaysia, is implementing and evaluating (compared to usual care) an evidence-based, contextually-appropriate program for CVD risk assessment, treatment and control involving simplified algorithms implemented by NPHWs, supported by e-health technologies; initiation of FDC of two antihypertensive drugs plus one statin; and use of treatment supporters to optimize long-term medication and lifestyle adherence. Both studies are ongoing with outcomes anticipated in the near future.

The use of a simplified strategy utilizing early introduction of inexpensive generic FDC pills (or ‘polypills’) is an approach with important potential to impact on what are currently exceedingly poor blood pressure control rates in LMICs. If found to be effective, cost-effective, and acceptable, this approach has the potential to impact the cardiovascular health of significant numbers of individuals around the world.

**Discussion**

Elevated blood pressure is the leading global risk for mortality,\(^1\) and novel approaches for improving hypertension control are urgently required for LMICs. The GACD hypertension studies described here are beginning to disseminate outcomes, results, and lessons in relation to several different innovative approaches. In addition, they are well-poised to develop post-study knowledge translation strategies. Finally, the GACD researchers have the potential to engage policy makers, payers, and other stakeholders, to translate the findings of individual research studies into sustainable and scalable interventions. Each GACD-funded project has designed one or more innovative approaches to enable the implementation and evaluation of interventions within local contexts, in order to improve care without significant disruption to, and increased workload of, already over-burdened health workers and health care systems.

All of the approaches described here have the potential to improve the cardiovascular health of populations in low-resource settings worldwide. Community engagement is a critical part of developing and introducing any new program, and increases the likelihood of successful uptake and implementation. Salt reduction and salt substitutes can reduce blood pressure and improve cardiovascular health, especially if combined with improved dietary intake of fresh...
fruits and vegetables. Task redistribution expands the reach of delegated medical acts, empowers and engages community members, improves health literacy of communities, and improves the efficiency of the existing pool of health care providers. mHealth can additionally provide decision support, remote medical record access, and novel educational interfaces, all of which can enhance care delivery in resource-limited settings. Finally, FDC pills have the potential to transform the landscape of medical management of hypertension and CVD. The studies outlined in this report demonstrate innovative and practical methods of implementing all of these strategies for hypertension control in diverse environments and contexts worldwide.

Acknowledgments

The writing group would like to thank Gary Parker from the GACD Secretariat for invaluable logistical and administrative support, and Drs. Clara Chow, Pallab Maulik, and Martin McKee for critical review of the manuscript. They would also like to thank all members of the GACD Hypertension Research Program for their support and input throughout the preparation of this manuscript. Funding for the studies described and for manuscript submission was provided by the following GACD Hypertension Program funding agencies: Canadian Institutes of Health Research (Grant No. 120389); Grand Challenges Canada (Grant Nos. 0069-04, and 0070-04); International Development Research Centre; Canadian Stroke Network; Australian National Health and Medical Research Council (Grant Nos. ID 1040147, and 104018); the US National Institutes of Health (National Heart, Lung and Blood Institute and National Institute of Neurological Disorders and Stroke) (Grant Nos. U01 HL114200, U01 NS079179, and U01 HL114180); the United Kingdom Medical Research Council (Grant Nos. APP 1040179, APP 1041052, and J01 60201); the Malaysian Ministry of Higher Education (Long-term Research Grants Scheme); and the South African Medical Research Council. This report does not represent the official view of the National Institute of Neurological Disorders and Stroke, the National Institutes of Health, or any part of the US Federal Government. No official support or endorsement of this article by the National Institutes of Health is intended or should be inferred.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP</td>
<td>Blood Pressure</td>
</tr>
<tr>
<td>CHW</td>
<td>Community Health Workers</td>
</tr>
<tr>
<td>CVD</td>
<td>Cardiovascular Disease</td>
</tr>
<tr>
<td>FDC</td>
<td>Fixed-Dose Combination Pills</td>
</tr>
<tr>
<td>FGD</td>
<td>Focus Group Discussions</td>
</tr>
<tr>
<td>GACD</td>
<td>Global Alliance for Chronic Diseases</td>
</tr>
<tr>
<td>I-RREACH</td>
<td>Intervention and Research Readiness Engagement and Assessment of Community Health Care</td>
</tr>
<tr>
<td>LMIC</td>
<td>Low- and Middle-Income Countries</td>
</tr>
<tr>
<td>NPHW</td>
<td>Non-physician Health Workers</td>
</tr>
<tr>
<td>TRIUMPH</td>
<td>TRIple Pill vs. Usual care Management for Patients with mild-to- moderate Hypertension</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
References


Cardiol Clin. Author manuscript; available in PMC 2018 February 01.


43. 60th WMA General Assembly. WMA Resolution on Task Shifting from the Medical Profession. New Delhi: World Medical Association; 2009.


Key Points

- Elevated blood pressure is a major risk factor for cardiovascular disease, and it is the leading global risk for mortality.
- There is a need for novel approaches when addressing hypertension due to its growing health and economic burden on LMIC populations.
- The Global Alliance for Chronic Diseases sponsored 15 research projects focused on hypertension.
- These research projects have involved the development and evaluation of several important innovative approaches to hypertension control, including: community engagement, salt reduction, salt substitution, task redistribution, mHealth, and fixed-dose combination therapies.
**Synopsis**

Elevated blood pressure, a major risk factor for ischemic heart disease, heart failure, and stroke, is the leading global risk for mortality. Despite global efforts to combat hypertension, treatment and control rates are very low in LMICs. Given the continued significant health and economic burden on LMIC populations, there is an urgent need to address the problem by way of novel approaches. The Global Alliance for Chronic Diseases sponsored 15 research projects focused on hypertension, which have involved the development and evaluation of several important innovative approaches to hypertension control, including: community engagement, salt reduction, salt substitution, task redistribution, mHealth, and fixed-dose combination therapies.
Figure 1.
Community engagement activities undertaken within GACD Projects. Participation activities denote the least level of engagement while empowerment activities denote the greatest level of engagement.
Figure 2.
Framework for salt reduction strategies, including context, activities, outputs, and anticipated outcomes.
Figure 3.
Launching a salt substitute to reduce blood pressure at the population level in Peru, divided into two phases.
Figure 4.
Figure 5.
Proportion of participants adherent to combination therapy at end of study in patients either with established CVD or at high calculated risk. Adherence is defined as taking antiplatelet, statin and ≥2 BP-lowering drugs at least 4 days of the last 7 at end of study in UMPIRE, Kanyini-GAP and IMPACT. Adherence in the FOCUS trial was defined as pill count between 80 and 110% at end of study plus a score of 20/20 on the Morisky-Green questionnaire. Data from references 73, 78, 79, 80.
Figure 6.
Schematic illustrating the potential for mHealth to connect clinicians, community health workers (CHWs), and patients. Blue arrows indicate direct interactions among individuals. Red arrows indicate interactions that are facilitated by mHealth.
Table 1

Type and target group of community engagement activities undertaken within GACD projects, including timing of engagement and materials developed through each activity.

<table>
<thead>
<tr>
<th>Region</th>
<th>Type</th>
<th>Target Group</th>
<th>Timing of Engagement</th>
<th>Rationale for Activity</th>
<th>Materials Developed</th>
</tr>
</thead>
<tbody>
<tr>
<td>INDIA</td>
<td>Community Entry</td>
<td>Community leaders</td>
<td>Prior to the initiation of study activities within each cluster/community unit</td>
<td>To gain entry into the community</td>
<td>Protocol, specific aims, abstract</td>
</tr>
<tr>
<td></td>
<td>Survey of community members</td>
<td>Individuals</td>
<td>Once at study initiation Length: 60–90 minutes</td>
<td>To identify barriers to seeking health care and/or treatment</td>
<td>Survey</td>
</tr>
<tr>
<td></td>
<td>Community Focus Group Discussions</td>
<td>Individuals with hypertension</td>
<td>Up to 12 focus groups, each comprising up to 10 people Length: 60–90 minutes</td>
<td>To identify barriers to seeking health care and/or treatment</td>
<td>Structured guide for discussions</td>
</tr>
<tr>
<td></td>
<td>In-depth interviews</td>
<td>Health care providers</td>
<td>23 interviews with doctors, nurses, and CHWs</td>
<td>To identify barriers to providing health care and/or treatment</td>
<td>Structured guide for interviews</td>
</tr>
<tr>
<td></td>
<td>Survey of medicines</td>
<td>Public, private and other medicine outlets</td>
<td>20 public outlets 16 private outlets 2 other outlets selling medicines at subsidized rates to all patients</td>
<td>To determine availability, affordability and acceptability of medications</td>
<td>Structured list of essential medicines for audit</td>
</tr>
<tr>
<td></td>
<td>Consultation via a planning day</td>
<td>Local, and state government health officials, and local experts</td>
<td>Once at a 4-hour planning session</td>
<td>To ensure that the design of the intervention fit into the health system</td>
<td>Final design of intervention</td>
</tr>
<tr>
<td></td>
<td>Working group testing of intervention materials</td>
<td>CHWs and local doctors</td>
<td>Over 5 days, CHWs and doctors participated in a pilot training program</td>
<td>To develop educational materials for training CHWs and to educate people with hypertension</td>
<td>Educational materials for training CHWs and for people with hypertension</td>
</tr>
<tr>
<td></td>
<td>Training</td>
<td>CHWs</td>
<td>5 full days of training delivered by doctors and researchers</td>
<td>To provide skills to CHWs to enable them to conduct a peer support group and educate people with hypertension</td>
<td>Education materials for CHWs</td>
</tr>
<tr>
<td></td>
<td>Community-based support group of people with hypertension</td>
<td>Letter of support and encouragement from head of village (Sarpanch)</td>
<td>3-month intervention comprising 6 fortnightly education sessions delivered by CHWs, locally sourced expert advisers, health care providers, and researchers</td>
<td>Self-management and education support group of people with hypertension</td>
<td>Education materials for people with hypertension, including handouts</td>
</tr>
<tr>
<td>Region</td>
<td>Type</td>
<td>Target Group</td>
<td>Timing of Engagement</td>
<td>Rationale for Activity</td>
<td>Materials Developed</td>
</tr>
<tr>
<td>-------------------</td>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------</td>
<td>-------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Dissemination of study results</td>
<td>Communities, local health providers, medicines outlets, Ministry of Health &amp; Welfare, National health Mission</td>
<td>At end of study</td>
<td>To build capacity and sustainability</td>
<td>Development of resources for use by health care providers for assessing and treating hypertension</td>
<td></td>
</tr>
<tr>
<td>Community Entry</td>
<td>Community leaders, health personnel, community stakeholders</td>
<td>Prior to the initiation of study activities within each cluster/community unit</td>
<td>To gain entry into the community</td>
<td>Protocol, specific aims, abstract, and PowerPoint summary</td>
<td></td>
</tr>
<tr>
<td>Community Gatherings (Mabaraza)</td>
<td>Community</td>
<td>Six in total (until content saturation achieved) Length: 1–2 hours</td>
<td>To identify the barriers and facilitators to linkage to care for hypertension and retention to care</td>
<td>Structured discussion guides for mabaraza</td>
<td></td>
</tr>
<tr>
<td>Focus Group Discussions</td>
<td>Individuals with hypertension and CHWs</td>
<td>17 total (until content saturation achieved) Length: 1–2 hours</td>
<td>To identify barriers to seeking and delivering health care and/or treatment</td>
<td>Moderator guides</td>
<td></td>
</tr>
<tr>
<td>Human-Centered Design</td>
<td>Design team with diverse stakeholders; content validity testing with diverse stakeholders</td>
<td>Occurrence: Approximately 10 design team meetings; nine content validity focus group discussions with patients, community health workers, and clinicians Length: 60 min</td>
<td>Design of behavioral assessment and tailored communication strategy</td>
<td>Final design of intervention</td>
<td></td>
</tr>
<tr>
<td>Community Entry</td>
<td>Community leaders/stakeholders</td>
<td>Prior to the initiation of study activities within each of the 2 selected communities</td>
<td>To gain entry into the community and gauge interest</td>
<td>Framework for development of the I-RREACH Tool</td>
<td></td>
</tr>
<tr>
<td>Completion of 3 'consensus' cycles</td>
<td>Stakeholders and community-based researchers in Canada and Tanzania</td>
<td>At project initiation moving forward over a 1 year period in 3 cycles</td>
<td>To test theoretical frameworks regarding researcher’s practice-based knowledge, community readiness, Indigenous approaches to research, empowerment approaches</td>
<td>Development of the I-RREACH Tool (insert Ref)</td>
<td></td>
</tr>
<tr>
<td>TANZANIA &amp; CANADA</td>
<td>Community Focus Group Discussions</td>
<td>Individuals with hypertension and their families as well as local health care providers</td>
<td>3 focus groups were held in participating Indigenous communities in Canada and 1 in Tanzania of varying length with a total of 45 participants</td>
<td>To identify major factors that may impact on the effectiveness of evidence-based educational SMS messages for people with hypertension and reduce health inequalities</td>
<td>Content from focus groups informed the development of the SMS messages to be used for the intervention in each country</td>
</tr>
<tr>
<td>Region</td>
<td>Type</td>
<td>Target Group</td>
<td>Timing of Engagement</td>
<td>Rationale for Activity</td>
<td>Materials Developed</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------------------</td>
<td>---------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Training</td>
<td>CHWs and local health providers</td>
<td>In the second year, CHWs and doctors participated in country specific training programs on hypertension and cardiovascular disease as well as use of the mHealth tools/equipment. In Tanzania there was also a pre-post evaluation of knowledge gained and an observed standardized clinical exam.</td>
<td>To prepare CHWs and health providers to provide educational support to their communities (people with hypertension and their families).</td>
<td>Educational materials for training CHWs and health providers.</td>
<td></td>
</tr>
<tr>
<td>Training</td>
<td>Local health providers (Tanzania only)</td>
<td>5 full days of training delivered by doctors and researchers in year 3 to evaluate the appropriateness of the treatment algorithm for management of hypertension (adapted from the existing Tanzanian hypertension guideline).</td>
<td>To provide skills to health providers to enable them to manage hypertension effectively.</td>
<td>Treatment algorithm for hypertension that is specific to low-resource rural setting in sub-Saharan Africa</td>
<td></td>
</tr>
<tr>
<td>Dissemination of study results</td>
<td>Communities, local health providers, medicines outlets, Ministry of Health &amp; Social Welfare, National health Mission</td>
<td>Will occur at end of study</td>
<td>To build capacity and sustainability.</td>
<td>Dissemination of resources for use by health care providers for assessing and treating hypertension.</td>
<td></td>
</tr>
<tr>
<td>Community social events or other non-clinical gatherings</td>
<td>Non-physician health workers attend the community events</td>
<td>NPHW attend events opportunistically with the permission of event organizers</td>
<td>Posters explaining the NPHW attendance; curated collections of local government brochures regarding CV health and other available health services; personalized healthy lifestyle counselling based on WHO recommendations (Intervention-only).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>